Added to YB: 2026-09-24
Pitch date: 2026-09-18
XENE [bullish]
Xenon Pharmaceuticals Inc.
-8.52%
current return
Author Info
Healthcare Investing Long / Short ideas. Sign up for the newsletter.
Company Info
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Market Cap
$3.8B
Pitch Price
$40.00
Price Target
60.00 (+53%)
Dividend
N/A
EV/EBITDA
-5.98
P/E
-8.41
EV/Sales
N/A
Sector
Biotechnology
Category
value
Flash note: Xenon: Selling overdone another good opportunity
XENE: Xenon’s voluntary pause in new enrollment for three depression trials appears over-penalized: there is no FDA hold, existing patients remain on drug, and the filed epilepsy program is unaffected after 1,500 patient-years of exposure. At $40, the shares offer a conservative $60 target, with psychiatric indications and other pipeline assets effectively free. The key risk is whether neuropsychiatric events lead to a boxed warning rather than Warnings and Precautions.
Read full article (2 min)